BioSpace News Archive

Scilex Holding Company announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List effective October 1, 2023.

Avidity Biosciences, Inc. today announced that Avidity management will be participating at the following upcoming conferences.

Shuttle Pharmaceuticals Holdings, Inc. today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application (PIND) meeting with the U.S. Food and Drug Administration (FDA).

Onco360 has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

AcuraStem announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) announces that, further to its press release of August 31, 2023, its management information circular (the “Circular”) and related materials were mailed today,

hC Bioscience has appointed Jose Lora, Ph.D., as its Chief Scientific Officer (CSO). In this position, Lora will play a pivotal role in helping to shape the Company’s strategic direction around its innovative portfolio of therapeutic tRNAs and advancing their lead candidates into the clinic.

Specialty cancer diagnostics company Precipio, Inc. announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required from the products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates.

Neuroendocrine Cancer treatment response test, PPQ, delivers 96% accuracy